Dengvaxia Dengue Vaccine Finally Gets Green Light From CDC’s Advisory Committee
Executive Summary
ACIP recommends Sanofi’s vaccine for use in persons 9 to 16 years old with a laboratory confirmation of previous dengue infection who are living in endemic areas. Recommendation comes two years after FDA licensure and following development of improved pre-vaccination screening tests.
You may also be interested in...
Communication Hurdles Remain For Sanofi’s Dengue Vaccine
CDC drafting recommendation for Sanofi’s Dengvaxia, setting parameters for required pre-vaccination screening in the absence of tests approved by the US FDA.
Keeping Track: US FDA Approves Sanofi’s Dengvaxia, But Heron’s HTX-011 And Nabriva’s Contepo Fall Short
The latest drug development news and highlights from our US FDA Performance Tracker.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.